1例EGFR 20外显子插入突变的非小细胞肺癌的合理用药分析  

Rational drug use in a case of non-small cell lung cancer with EGFR ex20ins mutation

作　　者：贺燕 李光灿 庄瑞春 陈芬 黄兴艳 HE Yan;LI Guang-can;ZHUANG Rui-chun(Department of Pharmacy,the People's Hospital of Kaizhou District,Chongqing 405400,China)

机构地区：[1]重庆市开州区人民医院药学部,405400

出　　处：《中国实用医药》2024年第9期136-139,共4页China Practical Medicine

摘　　要：为探讨临床上表皮生长因子受体(EGFR)20外显子插入突变的非小细胞肺癌的用药策略,本研究收集1例EGFR 20外显子插入突变的非小细胞肺癌患者的临床资料,并通过治疗过程监测、文献分析及事后用药分析进行探讨。在本病例中,阿美替尼与奥西替尼均为第三代酪氨酸激酶抑制剂(TKI)药物,将阿美替尼更换为阿法替尼并不是最佳的用药策略。对EGFR 20外显子插入突变的非小细胞肺癌的患者,化疗方案可以首选培美曲塞+顺铂(PP)方案,靶向药物首选奥西替尼或阿美替尼。This paper explores the optimal drug strategy for non-small cell lung cancer with epidermal growth factor receptor(EGFR)ex20ins mutation.The clinical data of a case of non-small cell lung cancer with EGFR ex20ins mutation was collected,and explored it through monitoring the treatment process,literature review and post-medication analysis.In this case,both allmetinib and osimertinib are third-generation tyrosine kinase inhibitors(TKIs),and switching from allmetinib to afatinib is not the best medication strategy.For non-small cell lung cancer with EGFR ex20ins mutation,pemetrexed+cisplatin(PP)regimen can be the best choice for chemotherapy,and osimertinib or Almetinib is the best choice for targeted drugs.

关 键 词：非小细胞肺癌 表皮生长因子受体20外显子插入突变 合理用药 

分 类 号：R734.2[医药卫生—肿瘤] R969.3[医药卫生—临床医学]